Skip to main content
OpenTrials
Completed

NCT Number: NCT07508592

Feasibility Study of the SEGER Device in Laparoscopic Gastrointestinal Surgery

This is a first-in-human feasibility study designed to evaluate the safety and performance of the SEGER device in patients undergoing elective laparoscopic gastrointestinal surgery requiring intracorporeal anastomosis.

The study will include patients undergoing procedures such as small bowel-small bowel and colorectal anastomoses. The SEGER device is intended to facilitate closure of enterotomies and support intracorporeal anastomosis during minimally invasive surgery.

The primary objective of the study is to assess the safety of the device and its performance during surgery. Secondary objectives include evaluation of technical success, intraoperative usability, and early postoperative outcomes.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This is a prospective, single-arm, first-in-human feasibility study designed to evaluate the safety and performance of the SEGER device in patients undergoing elective laparoscopic gastrointestinal surgery requiring intracorporeal anastomosis.

The study will be conducted at a single clinical site in El Salvador. Eligible patients are adults undergoing elective laparoscopic procedures involving intracorporeal anastomosis, including but not limited to small bowel-small bowel (e.g., jejuno-jejunal) and colorectal anastomoses.

The SEGER device is intended to facilitate closure of enterotomies and support the creation of intracorporeal anastomoses during minimally invasive surgery. The device will be used intraoperatively according to the study protocol and the investigator's clinical judgment.

The primary objective of the study is to evaluate the safety of the device, including the incidence of device-related and procedure-related adverse events. Secondary objectives include assessment of device performance, technical success, intraoperative usability, and early postoperative outcomes.

Patients will be followed postoperatively according to the study protocol to assess clinical outcomes and recovery. Data collected will include intraoperative parameters, device performance metrics, and postoperative clinical outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (e.g., age 18-80) who are candidates for
  • Laparoscopic ileocolic resection
  • Laparoscopic right hemicolectomy
  • Elective laparoscopic small bowel-small bowel anastomosis (including jejuno-jejunostomy and ileo-ileal anastomosis) performed as part of gastric bypass surgery (a maximum of 40% of the total enrolled population may consist of bariatric (gastric bypass) cases).
  • The surgeon has determined that an intracorporeal anastomosis is appropriate for the case,
  • The patient is able to provide informed consent and is willing to participate in the study, and
  • The patient has no condition that would preclude safe use of the device.

Exclusion criteria

  • Patients in emergency surgery situations (urgent cases where study enrollment and the careful use of a new device are not feasible),
  • Patients with extensive intra-abdominal adhesions or anatomical abnormalities that would make intracorporeal anastomosis technically impossible,
  • Patients with a known hypersensitivity to titanium or stainless steel (although rare, this relates to staple/anvil materials),
  • Pregnant patients.
  • Patients with severe uncontrolled coagulopathy or other high-risk medical conditions that, in the judgment of the investigator and surgical team, do not allow for a safe surgical procedure

Treatment and study plan

SEGER Device

Device

The SEGER device is an investigational surgical device used during laparoscopic gastrointestinal procedures to facilitate intracorporeal closure of enterotomies and support small bowel anastomosis. The device is applied intraoperatively as part of the surgical workflow.

Primary outcomes

  1. Incidence of anastomotic leaks

    Time frame: Within 30 days post-surgery

    Incidence of anastomotic leaks within 30 days post-surgery, assessed by clinical symptoms, imaging findings, or need for reoperation.

Secondary outcomes

  1. Technical success rate

    Time frame: Intraoperative

    Proportion of procedures with successful deployment of the SEGER IDEA™ device without intraoperative complications.

  2. Incidence of postoperative complications

    Time frame: Within 30 days post-surgery

    Incidence of postoperative complications including bleeding, infection, stricture formation, or device-related adverse events.

  3. Time to complete enterotomy closure

    Time frame: Intraoperative

    Time from device deployment to completion of enterotomy closure.

  4. Length of hospital stay

    Time frame: Up to 30 days post-surgery

    Number of days from surgery to hospital discharge.

  5. Need for additional intraoperative interventions

    Time frame: Intraoperative

    Use of additional techniques such as reinforcement suturing or alternative closure methods.

  6. Patient recovery outcomes

    Time frame: Within 30 days post-surgery

    Time to return to normal diet, bowel function, and physical activity.

Sponsors and collaborators

Lead sponsor

Seger Surgical Solutions

Industry

Registry information

Official study title

A Prospective Study on the Usability and Clinical Outcomes of the SEGER IDEA™ Device for Enterotomy Closure

Acronym: SEGER-FIH

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 2, 2026
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.